EMA clarifies definition of Type II quality variations in revised fee rules for pharma
This article was originally published in SRA
Executive Summary
The European Medicines Agency has adopted revised rules on drug-related fees to clarify the definition of Type II quality variations and to explain the mechanism for compensating national competent authorities and inspectorates for their work at the agency1,2.